M&A Buyout – Project Rover

Work Smarter, Not Harder. 

Check out our tools which include pitch decks based on real, successful deals, and quickly learn how the top IBs structure their presentations.

🔄 What is Revenue Cycle Management (RCM)?

Revenue Cycle Management (RCM) encompasses the processes healthcare organizations use to track and manage revenue from the initial patient appointment  to the final payment. In simpler terms, it ensures healthcare providers are paid for their services, covering everything from scheduling appointments to collecting payments. The process has many steps, as illustrated in the image below.

🏥 Industry Snapshot: Healthcare RCM on the Rise?

Demand for RCM software companies in healthcare has surged as hospitals focus on efficiency and revenue capture. With rising healthcare costs, providers face mounting pressure to manage expenses while maximizing the revenues collected from patient services. This urgency has made streamlined RCM solutions essential, enabling providers to better focus on care without losing income to billing complexities.

The numbers reflect this trend: Yahoo Finance estimates the market will reach $238.4 billion, with Grand View Research projecting a 10.3% CAGR until 2030 in North America only.

Managing today’s complex billing landscape is indeed no small task. With numerous insurers and extensive billing rules, many healthcare providers rely on RCM solutions to avoid costly errors and reduce administrative hurdles. As digital transformation gains momentum, cloud-based and AI-driven tools are both helping hospitals minimize revenue leakage and improve accuracy, directly impacting their bottom line.

This trend reflects growing venture capital interest in healthcare technology. Investors are increasingly attracted to scalable solutions that promise significant improvements in operational efficiency and patient outcomes. As the sector evolves, there is more focus on startups that leverage innovative technologies to integrate seamlessly into existing healthcare systems, underscoring the demand for results-driven solutions.

Rover – Company Background

Founded in 2003 with the aim of enhancing revenue management for healthcare systems, Rover has expanded its reach to over 3,700 hospitals and 30,000 physicians across the U.S., representing over $1 trillion in Net Patient Revenue (NPR) by the end of 2023. Key shareholders include NMC, which owns approximately 30% on a diluted basis, and TCP-ASC, a joint venture between TowerBrook Capital Partners and Ascension Health System, holding about 33%.

Refined Offer and Due Diligence

NMC made an initial offer by the end of January 2024 to acquire all shares (not owned by NMC) for $13.75 per share. Despite its willingness to transact, Rover’s special committee still decided to request their advisors to do a quick market sounding to gauge investor appetite. However, none of the five strategic buyers approached showed interest, which prompted the committee to resume negotiations with NMC.

NMC’s process involved over 500 diligence requests, leading to a revised offer of $13.25 per share in July, which incorporated key findings from due diligence. Although Rover's stock temporarily dipped following the public disclosure of this update, advisors calculated a DCF value that aligned the revised offer with industry norms. Additionally, trading comps further supported that the adjusted price remained within standard valuation ranges for the sector.

Committee Considerations and Deal Closure

As the Special Committee analyzed growth forecasts, they weighed the potential value of Rover remaining independent. Optimism was fueled by consistent projected gains from enhanced end-to-end services and operational synergies through AI, though concerns about customer retention tempered this outlook. After discussions, both parties aligned on terms that highlighted premium benefits and future growth potential.

All This Work For… Nothing?

Just as NMC was finalizing plans for Rover’s acquisition, TowerBrook Capital Partners and Clayton, Dubilier & Rice (CD&R) entered the scene with an all-cash buyout. Their offer of $14.30 per share represented a 29% premium over Rover’s pre-bid share price, highlighting the competitive appetite for healthcare revenue cycle management (RCM) assets in a rapidly consolidating market.

For NMC, this development shifted the competitive landscape, prompting a potential strategic recalibration as RCM becomes integral to operational efficiency across healthcare. Meanwhile, TowerBrook and CD&R’s substantial investments in AI and automation reinforce their commitment to Rover’s potential to innovate and set new standards in the sector.

✒ On a Final Note…

Now under new ownership, Rover is well-positioned for strategic expansion and operational synergies as a private entity. TowerBrook and CD&R's vision for enhancing intelligent automation could set new benchmarks in the industry, leaving NMC to reassess its strategy in a rapidly evolving sector. The use of DCF analysis in this transaction is a solid reminder that it’s worth staying sharp with these models - they come in handy when deals like this come across your desk.

Enjoyed this read? Don’t hesitate to share your thoughts and feedback by responding to this email. I’d love to hear from you.

Until next time,
PE Bro

P.S. Was this email forwarded to you? Then subscribe here!